Search

1 to 10 of 66
Sort by

Library Entry
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the...


Library Entry
Master protocols in immuno-oncology: do novel drugs deserve novel designs?

The rapid rise to fame of immuno-oncology (IO) drugs has generated unprecedented interest in the industry, patients and doctors, and has had a major impact in the treatment of most cancers. An interesting aspect in the clinical development of many IO agents is the increasing reliance on...


Library Entry
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...




Library Entry
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Using the National Cancer Database, the authors identified 4725 patients aged ≥20 diagnosed with...



Library Entry
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost...


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Miami Webinar 1

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Miami event is provided here. The purpose of this...

Advances in Cancer Immunotherapy™ Post-Program Webinar 1 (Miami).mp4


Library Entry
2018 Advances in Cancer Immunotherapy™ Post Program Webinar Series - Dallas Webinar 2

From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Dallas event is provided here. The purpose of...

Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Dallas).mp4